DK0809996T3 - Interferonkonjugater - Google Patents

Interferonkonjugater

Info

Publication number
DK0809996T3
DK0809996T3 DK97108261T DK97108261T DK0809996T3 DK 0809996 T3 DK0809996 T3 DK 0809996T3 DK 97108261 T DK97108261 T DK 97108261T DK 97108261 T DK97108261 T DK 97108261T DK 0809996 T3 DK0809996 T3 DK 0809996T3
Authority
DK
Denmark
Prior art keywords
interferon
Prior art date
Application number
DK97108261T
Other languages
English (en)
Inventor
Pascal Sebastian Bailon
Alicia Vallejo Palleroni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21790006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0809996(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0809996T3 publication Critical patent/DK0809996T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97108261T 1996-05-31 1997-05-22 Interferonkonjugater DK0809996T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1883496P 1996-05-31 1996-05-31

Publications (1)

Publication Number Publication Date
DK0809996T3 true DK0809996T3 (da) 2003-07-21

Family

ID=21790006

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97108261T DK0809996T3 (da) 1996-05-31 1997-05-22 Interferonkonjugater

Country Status (47)

Country Link
US (1) US7201897B2 (da)
EP (1) EP0809996B1 (da)
JP (1) JP2980569B2 (da)
KR (1) KR100254097B1 (da)
CN (1) CN1088721C (da)
AR (1) AR008378A1 (da)
AT (1) ATE235920T1 (da)
AU (1) AU725195B2 (da)
BG (1) BG62273B1 (da)
BR (1) BR9703421A (da)
CA (1) CA2203480C (da)
CO (1) CO4950528A1 (da)
CY (2) CY2433B1 (da)
CZ (1) CZ292775B6 (da)
DE (3) DE10399018I1 (da)
DK (1) DK0809996T3 (da)
EG (1) EG24292A (da)
ES (1) ES2110386T3 (da)
GR (1) GR970300063T1 (da)
HR (1) HRP970298B1 (da)
HU (1) HU227992B1 (da)
IL (1) IL120902A (da)
IS (1) IS1988B (da)
LU (1) LU91029I2 (da)
MA (1) MA24193A1 (da)
MY (1) MY117909A (da)
NL (1) NL300127I2 (da)
NO (1) NO322964B1 (da)
NZ (1) NZ314903A (da)
OA (1) OA10488A (da)
PA (1) PA8431001A1 (da)
PL (1) PL186949B1 (da)
PT (1) PT809996E (da)
RS (1) RS49533B (da)
RU (1) RU2180595C2 (da)
SA (1) SA97180030B1 (da)
SG (1) SG55314A1 (da)
SI (1) SI0809996T1 (da)
SK (1) SK284458B6 (da)
SV (1) SV1997000049A (da)
TJ (1) TJ328B (da)
TN (1) TNSN97091A1 (da)
TR (1) TR199700358A3 (da)
TW (1) TW517067B (da)
UA (1) UA56989C2 (da)
UY (1) UY24572A1 (da)
ZA (1) ZA974583B (da)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
PT858343E (pt) 1995-11-02 2004-07-30 Schering Corp Terapia por infusao continua de uma dose baixa de citoquina
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
EP1066059B1 (en) * 1998-03-26 2005-06-15 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
EA003789B1 (ru) * 1998-04-28 2003-10-30 Апплайд Резеч Системз Арс Холдинг Н.В. КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН
BR9910505A (pt) 1998-05-15 2001-01-02 Schering Corp Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
HRP20000808A2 (en) * 1998-06-08 2001-10-31 Hoffmann La Roche Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
TWI271196B (en) * 1999-04-08 2007-01-21 Schering Corp CML therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
ES2239954T3 (es) 1999-04-08 2005-10-16 Schering Corporation Terapia contra el melanoma.
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
CZ20022727A3 (cs) 2000-01-10 2002-11-13 Maxygen Holdings Ltd Polypeptidový konjugát, způsob jeho výroby a farmaceutický prostředek
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
CA2397793A1 (en) * 2000-01-24 2001-07-26 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
US6806063B2 (en) 2000-02-11 2004-10-19 Maxygen Aps Factor VII or VIIa-like molecules
US6476062B2 (en) 2000-03-30 2002-11-05 Schering Corporation Chemokine receptor antagonists
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6927040B2 (en) 2000-06-30 2005-08-09 Zymogenetics, Inc. Interferon-like protein Zcyto21
CA2436623C (en) 2001-01-30 2011-08-02 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
EP2080771A3 (en) 2001-02-27 2010-01-06 Maxygen Aps New interferon beta-like molecules
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
WO2003062290A1 (en) 2002-01-16 2003-07-31 Biocompatibles Uk Limited Polymer conjugates
KR100888371B1 (ko) * 2002-01-17 2009-03-13 동아제약주식회사 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
ES2363205T3 (es) 2002-06-21 2011-07-26 Novo Nordisk Health Care Ag Glicoformas del factor vii pegilado.
AU2003258518B2 (en) 2002-07-24 2007-01-18 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
DE02020425T1 (de) * 2002-09-11 2004-07-15 Fresenius Kabi Deutschland Gmbh Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
EP1681303B1 (en) * 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
PL217085B1 (pl) * 2002-09-11 2014-06-30 Fresenius Kabi Gmbh Koniugat hydroksyalkiloskrobi i polipeptydu, sposób wytwarzania koniugatu hydroksyalkiloskrobi i polipeptydu, zastosowanie koniugatu hydroksyalkiloskrobi i polipeptydu oraz kompozycja farmaceutyczna koniugatu hydroksyalkiloskrobi i polipeptydu
TWI318629B (en) * 2002-09-20 2009-12-21 Pharmacia Corp Process for decreasing aggregate levels of pegylated protein
DE60323756D1 (de) 2002-10-08 2008-11-06 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CA2504267A1 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
ATE481420T1 (de) 2003-10-10 2010-10-15 Novo Nordisk As Il-21-derivate
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
JP4889505B2 (ja) 2004-02-02 2012-03-07 アンブレツクス・インコーポレイテツド 被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
EP2336192A1 (en) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
BRPI0511196A (pt) 2004-05-19 2007-12-04 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006004959A2 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
KR20070039593A (ko) 2004-07-21 2007-04-12 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
KR20070045244A (ko) 2004-08-12 2007-05-02 쉐링 코포레이션 안정한 페길화된 인터페론 제형
MX2007007580A (es) 2004-12-22 2007-12-11 Ambrx Inc Hormona del crecimiento humana modificada.
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
CN101501068A (zh) 2005-05-18 2009-08-05 马克西根公司 改进的α-干扰素多肽
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CN101257925A (zh) * 2005-06-20 2008-09-03 派普根公司 人干扰素α类似物和干扰素τ的低毒长循环的嵌合体
DK1937824T3 (da) 2005-08-18 2013-04-02 Ambrx Inc Sammensætninger af tRNA og anvendelser deraf
JP4261531B2 (ja) 2005-09-06 2009-04-30 株式会社Ｎｒｌファーマ ラクトフェリン複合体及びその製造方法
KR20080079643A (ko) 2005-11-16 2008-09-01 암브룩스, 인코포레이티드 비-천연 아미노산을 포함하는 방법 및 조성물
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
AU2007250739A1 (en) 2006-05-16 2007-11-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treating or preventing HCV infection
CA2653154A1 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Prolonged fix analogues and derivatives
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
WO2008030613A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
CN1966547B (zh) * 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
US9458256B2 (en) * 2006-11-07 2016-10-04 Dsm Ip Assets B.V. Carbamate, thiocarbamate or carbamide comprising a biomolecular moiety
KR101079993B1 (ko) 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
JP5515224B2 (ja) 2007-02-28 2014-06-11 日油株式会社 多分岐鎖ポリオキシアルキレン誘導体
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
PL2186830T3 (pl) 2007-09-04 2012-09-28 Biosteed Gene Expression Tech Co Ltd Interferon alfa 2b zmodyfikowany glikolem polietylenowym, jego wytwarzanie i zastosowanie
ES2386575T3 (es) 2007-09-04 2012-08-23 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
CN101918430A (zh) * 2008-01-18 2010-12-15 弗·哈夫曼-拉罗切有限公司 非糖基化蛋白质的纯化
PL2237799T3 (pl) * 2008-02-01 2019-09-30 Ascendis Pharma A/S Prolek zawierający samorozszczepiający się łącznik
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
CN101809038B (zh) 2008-04-03 2013-10-30 厦门伯赛基因转录技术有限公司 双链聚乙二醇修饰的生长激素及其制备方法和应用
CA2721947C (en) * 2008-04-29 2016-03-08 Ascendis Pharma As Pegylated recombinant human growth hormone compounds
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
EA020766B1 (ru) 2008-07-08 2015-01-30 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
DK2342223T3 (da) 2008-09-26 2017-07-24 Ambrx Inc Modificerede dyre-erythropoietin-polypeptider og deres anvendelser
MX357314B (es) 2008-09-26 2018-07-04 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
IT1399351B1 (it) 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
RU2012129674A (ru) 2009-12-15 2014-01-27 Аспендис Фарма Ас Композиция гормона роста
PE20121799A1 (es) 2009-12-21 2013-01-02 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
CA2803093A1 (en) 2010-06-24 2011-12-29 Panmed Ltd. Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
CA2805564A1 (en) 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
SMT202400182T1 (it) 2010-08-17 2024-07-09 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
CN102229667A (zh) * 2011-06-03 2011-11-02 北京伟嘉人生物技术有限公司 一种聚乙二醇修饰的猪α-干扰素及其制备方法和应用
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
BR112014002365A2 (pt) 2011-08-03 2017-02-21 Cytheris interleucina-7 (il-7)
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
EA023323B1 (ru) * 2013-03-28 2016-05-31 Илья Александрович МАРКОВ Разветвленный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
EA022617B1 (ru) * 2013-03-28 2016-02-29 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EP3336103B1 (en) 2013-07-10 2021-03-17 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
RU2554761C1 (ru) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Противоэнтеровирусное и иммуностимулирующее средство
EP3412302B1 (en) 2014-10-24 2021-05-12 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
KR102540109B1 (ko) 2014-11-06 2023-06-02 파마에센시아 코퍼레이션 Peg화된 인터페론의 투약 요법
RU2718664C2 (ru) 2014-11-18 2020-04-13 Асцендис Фарма Эндокринолоджи Дивижн А/С НОВЫЕ ПОЛИМЕРНЫЕ hGH ПРОЛЕКАРСТВА
PL3220892T3 (pl) 2014-11-21 2022-01-31 Ascendis Pharma Endocrinology Division A/S Postacie dawkowane długo działającego hormonu wzrostu
CA2999944A1 (en) 2015-11-03 2017-05-11 F.Hoffmann-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and an interferon
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
RU2678332C1 (ru) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
JP7695885B2 (ja) 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
JP7524206B2 (ja) 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー／エス １日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
MX2022011163A (es) 2020-03-11 2022-10-18 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
CN116916966A (zh) * 2020-12-23 2023-10-20 爵士制药爱尔兰有限公司 纯化电荷屏蔽融合蛋白的方法
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications
CN120676956A (zh) 2023-02-09 2025-09-19 谢彦晖 聚乙二醇修饰的白介素2、糖皮质激素和透明质酸用于治疗特应性皮炎

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681848A (en) 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
WO1984004745A1 (fr) 1983-05-31 1984-12-06 Takeda Chemical Industries Ltd Nouveaux polypeptides et leur utilisation
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5145773A (en) * 1989-05-25 1992-09-08 Sloan-Kettering Institute For Cancer Research Method to detect sensitivity to alpha-interferon therapy
DK0400472T3 (da) * 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
US5238915A (en) 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
GB9111967D0 (en) 1991-06-04 1991-07-24 Erba Carlo Spa 2,5'-nucleotide analogs as antiviral agents
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
RU2006036C1 (ru) * 1991-12-27 1994-01-15 Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи РАМН Способ определения антигенов
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5711944A (en) * 1993-11-10 1998-01-27 Enzon, Inc. Interferon polymer conjugates
WO1995021629A1 (en) * 1994-02-08 1995-08-17 Amgen Inc. Oral delivery of chemically modified proteins
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay

Also Published As

Publication number Publication date
NO322964B1 (no) 2006-12-18
EP0809996A3 (en) 1999-04-14
TJ97000465A (en) 1998-12-25
NZ314903A (en) 1998-10-28
EG24292A (en) 2009-01-08
SK284458B6 (sk) 2005-04-01
YU17597A (sh) 1999-07-28
SV1997000049A (es) 1998-07-09
JP2980569B2 (ja) 1999-11-22
BG62273B1 (bg) 1999-07-30
RS49533B (sr) 2006-12-15
IS4491A (is) 1997-12-01
CY2005006I1 (el) 2009-11-04
ES2110386T1 (es) 1998-02-16
HU227992B1 (en) 2012-08-28
CZ167997A3 (en) 1997-12-17
PT809996E (pt) 2003-06-30
BG101540A (en) 1998-02-27
NL300127I2 (nl) 2003-09-01
AU2372397A (en) 1997-12-04
EP0809996B1 (en) 2003-04-02
DE10399018I1 (de) 2003-10-23
ZA974583B (en) 1998-11-17
BR9703421A (pt) 1998-09-15
TJ328B (en) 2001-12-24
MY117909A (en) 2004-08-30
OA10488A (fr) 2002-04-11
NO972480L (no) 1997-12-01
PA8431001A1 (es) 2000-05-24
IL120902A (en) 2004-06-20
LU91029I2 (fr) 2004-01-23
HK1005225A1 (en) 1998-12-31
DE69720320T2 (de) 2004-06-03
TR199700358A2 (xx) 1997-12-21
DE809996T1 (de) 1998-04-09
ES2110386T3 (es) 2003-10-01
CY2433B1 (en) 2004-11-12
KR100254097B1 (ko) 2000-05-01
MX9704012A (es) 1997-11-29
UY24572A1 (es) 2000-12-29
ATE235920T1 (de) 2003-04-15
JPH1067800A (ja) 1998-03-10
EP0809996A2 (en) 1997-12-03
UA56989C2 (uk) 2003-06-16
KR970074791A (ko) 1997-12-10
IS1988B (is) 2005-02-15
HUP9700959A3 (en) 1998-03-30
HRP970298B1 (en) 2003-08-31
NL300127I1 (da) 2003-07-01
SA97180030B1 (ar) 2005-11-12
SI0809996T1 (en) 2003-08-31
HU9700959D0 (en) 1997-07-28
CO4950528A1 (es) 2000-09-01
US7201897B2 (en) 2007-04-10
GR970300063T1 (en) 1998-01-30
IL120902A0 (en) 1997-09-30
CZ292775B6 (cs) 2003-12-17
AU725195B2 (en) 2000-10-05
CA2203480C (en) 2009-06-30
PL186949B1 (pl) 2004-04-30
CY2005006I2 (el) 2009-11-04
PL320251A1 (en) 1997-12-08
TW517067B (en) 2003-01-11
TR199700358A3 (tr) 1997-12-21
HUP9700959A2 (hu) 1998-03-02
CA2203480A1 (en) 1997-11-30
SK67397A3 (en) 1997-12-10
DE69720320D1 (de) 2003-05-08
SG55314A1 (en) 1998-12-21
AR008378A1 (es) 2000-01-19
US20040030101A1 (en) 2004-02-12
CN1088721C (zh) 2002-08-07
CN1167777A (zh) 1997-12-17
TNSN97091A1 (fr) 2005-03-15
RU2180595C2 (ru) 2002-03-20
NO972480D0 (no) 1997-05-30
MA24193A1 (fr) 1997-12-31
HRP970298A2 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
DK0809996T3 (da) Interferonkonjugater
DK0736303T3 (da) Interferonopløsning
ATE208395T1 (de) Thiophenopyrimidine
ATE262512T1 (de) Arylalkanoylpyridazine
ATE208773T1 (de) Chinoxalindione
NO963385D0 (no) Böyebegrenser
ATE353652T1 (de) Östroprogestatives antikonzeptionsmittel
DK0936872T4 (da) Slik-legetöj
NO974125D0 (no) N-benzylazoliumderivater
NO301847B1 (no) Snubbinganordning
ID16384A (id) Larutan interferon
KR970050198U (ko) 개량감지기
BR9600867A (pt) Conjunto empacotadora-enfardadora
ATE267568T1 (de) Epithese
BR7600030U (pt) Cinturita
BR7601720U (pt) Paraglayder
FI964458A0 (fi) Naolfoerare
BR7600260U (pt) Multi-morsa
BR7600429U (pt) Hidrolax
BR7601310U (pt) Microlivro
BR7601419U (pt) Mourao
BR7601508U (pt) Cogafa
FI963906A0 (fi) Snoetraemetod foer skogsbruk
BR7601509U (pt) Gafa
FI963193A0 (fi) Demokrator